Inclusion Criteria:

        Written informed consent must be obtained prior to any screening procedures. Patients must
        meet all Inclusion Criteria:

          -  Patient is able to communicate well with the investigator, to understand and comply
             with the requirements of the study.

          -  Patients must be 18 years of age or older; elderly patients must be fit to receive
             intensive induction and consolidation chemotherapy

          -  Patients must have a documented FLT3 mutation (ITD or TKD)

          -  Patients must have an ECOG Performance Status of ≤ 2

          -  Patients must have a documented unequivocal diagnosis of AML according to WHO 2008
             classification (>20% blasts in the bone marrow and/or peripheral blood), excluding M3
             (acute promyelocytic leukemia).

          -  Patients requiring intrathecal chemotherapy must have a minimum washout of 48 hours
             prior to the first dose of midostaurin

          -  AML patients with a history of antecedent treatment for myelodysplasia (MDS), e.g.
             azacitidine or decitabine, remain eligible for treatment on this study. These agents
             must have been discontinued for a period of at least 30 days or 5 half-lives of the
             drug (whichever is greater) before midostaurin can be administered.

          -  Secondary AML, e.g. patients with antecedent history of treatment for prior malignancy
             Patients must have the following laboratory values (Direct Bilirubin ≤ 2.5 x ULN,
             Serum Creatinine ≤ 2.5 x ULN)

        Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

          -  Prior therapy for AML with the following exceptions: (emergency leukapheresis,
             emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days, cranial RT
             for CNS leukostasis (one dose only), growth factor/cytokine support)

          -  Patients with LVEF less than 45% (by echocardiogram or MUGA) or symptomatic congestive
             heart failure, Class III or IV according to New York Heart Association (NYHA)
             classification

          -  Patients with any uncontrolled illness, including, but not limited to, acute or
             chronic pancreatitis or uncontrolled infection

          -  QTc >500 msec on screening ECG. History of hypersensitivity to any drugs or
             metabolites of similar chemical classes as the IMP.

          -  Participation in a prior investigational interventional (drug) study with
             administration of the investigational product within 30 days or 5 half-lives of the
             investigational product, whichever is longer.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle, or sexual orientation
             precludes intercourse with a male partner and women whose partners have been
             sterilized by vasectomy or other means, UNLESS they are using two birth control
             methods.

          -  Sexually active males should not father a child during this study and for upto 5
             months following.